Prognostic factors and efficacy of postoperative chemotherapy in patients with gastric cancer with positive peritoneal cytology after gastrectomy

Table 5 Details of chemotherapy

	Conventional chemotherapy (n = 25)	New combination chemotherapy (n = 17)	P value
TI until the postoperative CTx (week)1	5.1 (1.9-9.1)	5.1 (1.4-10.6)	0.908
TTF (months)
Oral drug	12.6(1.6-49.0)	17.0 (3.0-45.8)	0.129
Intravenous	5.3 (1.2-8.6)	5.4 (2.1-11.4)	0.946
Course: Median (range)
Intravenous	3.6 (1-5)	6.2 (2-15)	0.098
RDI: Median (%)
Intravenous	74.5 (54.5-100)	82.1 (60.9-100)	0.276
< 80%: > 80%	4:2	7:10	0.001
Adverse event (grade III)2	8 (32%)	17 (71%)	0.014
Reason for CTx discontinuation
Recurrence: Adverse events, etc.3	15:4:6	4:4:9	0.051
Subsequent CTx after recurrence	10/15 (67%)	2/4 (50%)	0.475

¹Time interval until the postoperative chemotherapy refers to the period between surgery and the initiation of chemotherapy.

²Common Terminology Criteria for Adverse Event v5.0.

³Includes planned cessation, long-term administration, and ongoing treatment.

TI: Time interval; CTx: Chemotherapy; TTF: Time to failure; RDI: Relative dose intensity.